To: The Editor, Washington Post
RE: Biotech Bottleneck
Your editorial, Biotech Bottleneck, doesn’t consider the many patients waiting for new therapies and cures, and the millions of older Americans who need safe medications. Your proposed biosimilars pathway is the least safe and the one most likely to destroy the pipeline to new treatments and cures that will save millions of lives and billions of dollars.
read more ...